PEG3350 Plus Lactulose vs Lactulose Alone in ACLF With Overt Hepatic Encephalopathy

Phase 4, randomised, single-blind trial of polyethylene glycol 3350 in hepatic encephalopathy (HE) and acute-on-chronic liver failure (ACLF) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Improvement in survival at 90 days and Improvement of encephalopathy by one or more grades at 72 hours. Status: unknown.